Doxapram versus placebo in preterm newborns: An international double blinded multicenter randomized controlled trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515625-29-00

Acronym

NL72125.078.19

Enrollment

300

Registered

2024-11-11

Start date

2020-06-16

Completion date

Unknown

Last updated

2024-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Apnea of prematurity

Brief summary

Primary outcome will be the composite outcome of death or severe disability at the age of 18-24 months corrected age. Both outcomes will also be analyzed seperately.

Interventions

DRUGGlucose 5% 50 ml

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
Primary outcome will be the composite outcome of death or severe disability at the age of 18-24 months corrected age. Both outcomes will also be analyzed seperately.	—

Countries

Belgium, Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026